KASID
Search
- Page Path
- HOME > Search
Original Article
- IBD
- Effectiveness of transabdominal ultrasonography in predicting clinical relapse of Crohn’s disease
- Shinya Fukushima, Takehiko Katsurada, Mutsumi Nishida, Satomi Omotehara, Kensuke Sakurai, Kana Yamanashi, Reizo Onishi, Naoya Sakamoto
- Intest Res 2024;22(1):82-91. Published online January 29, 2024
- DOI: https://doi.org/10.5217/ir.2023.00093
-
Abstract
PDF
Supplementary Material
PubReader
ePub - Background/Aims
Transabdominal ultrasonography (US) helps evaluate Crohn’s disease (CD) activity. We investigated whether the US could predict subsequent adverse outcomes for patients with CD in clinical remission.
Methods
This single-center retrospective study included patients with CD in clinical remission who underwent US between April 2011 and April 2021, focusing on the predictability of subsequent adverse outcomes within 5 years. We used the US-CD, which was calculated using multiple US findings. Predictive variables were assessed using Cox proportional hazards regression analysis, and the predictive value was evaluated using receiver operating characteristic curves.
Results
Seventy-three patients were included. During a median follow-up of 1,441 days (range, 41–1,825 days), 16.4% (12/73) experienced clinical relapse, 9.6% (7/73) required endoscopic balloon dilation (EBD), 58.9% (43/73) required enhanced treatment, and 20.5% (15/73) underwent surgery. In the multivariate analysis, US-CD was significantly associated with clinical relapse (P= 0.038) and the need for enhanced treatment (P= 0.005). The area under the receiver operating characteristic curve for predicting clinical relapse and the need for EBD was 0.77 and 0.81, respectively, with US-CD (cutoff value = 11), and that for requiring enhanced treatment was 0.74 with US-CD (cutoff value = 6). Patients with US-CD ≥ 11 demonstrated a significantly higher occurrence of clinical relapse (P= 0.001) and EBD (P= 0.002) within 5 years. Patients with US-CD ≥ 6 experienced a significantly higher likelihood of requiring enhanced treatment (P< 0.001) within 5 years.
Conclusions
High US-CD is associated with subsequent adverse outcomes in patients with CD. -
Citations
Citations to this article as recorded by
- Non-invasive monitoring of inflammatory bowel disease using intestinal ultrasound
Hakima Abid, Hajar Cherkaoui, Fatima Benahsine, Asmae Lamine, Maria Lahlali, Ismail Chaouche, Fatima Bartal, Nada Lahmidani, Amine Elmekkaoui, Dafr Allah Benajah, Mohammed Abkari, Sidi Adil Ibrahimi, Karima Elghazi, Mustapha Maaroufi, Mounia Elyousfi
World Journal of Gastrointestinal Endoscopy.2025;[Epub] CrossRef - Intestinal ultrasound in Crohn’s disease: A systematic review of its role in diagnosis, monitoring, and treatment response
Partha Pal, Mohammad Abdul Mateen, Kanapuram Pooja, Nandhakumar Rajadurai, Rajesh Gupta, Manu Tandan, Nageshwar Reddy Duvvuru
World Journal of Meta-Analysis.2025;[Epub] CrossRef - ECCO-ESGAR-ESP-IBUS Guideline on Diagnostics and Monitoring of Patients with Inflammatory Bowel Disease: Part 1
Torsten Kucharzik, Stuart Taylor, Mariangela Allocca, Johan Burisch, Pierre Ellul, Marietta Iacucci, Christian Maaser, Pamela Baldin, Gauraang Bhatnagar, Shomron Ben-Horin, Dominik Bettenworth, Mallory Chavannes, Ann Driessen, Emma Flanagan, Frederica Fur
Journal of Crohn's and Colitis.2025;[Epub] CrossRef
- Non-invasive monitoring of inflammatory bowel disease using intestinal ultrasound
- 4,757 View
- 150 Download
- 2 Web of Science
- 3 Crossref
First
Prev
